Thanks for the link.
Still very vague & shady. “increased demand” or “manufacturing issues” is pretty non-descript.
Interesting, Isoniazid was listed as being short due to increased demand. That’s the drug used to treat TB.
Due to the recession, businesses are cutting marginal, low profit products. In addition, drug companies do not want to be mandated to continue to produce low margin drugs when Obamacare fully kicks in.